Kidney filter study tests safer dialysis for acute kidney failure

NCT ID NCT07679568

Not yet recruiting Knowledge-focused Sponsor: Fresenius Medical Care Deutschland GmbH Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study looks at how well a specific kidney filter (multiFlux 160) works when used with two different blood thinners—heparin or citrate—during continuous kidney replacement therapy. The goal is to see which approach keeps the filter working effectively while avoiding side effects like electrolyte imbalances. The study includes adults and children with acute kidney injury who need this therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: multiFlux 160 hemofilter
What this could lead to: If successful, this study could help doctors choose the best blood thinner for kidney dialysis in critically ill patients, potentially improving treatment safety and effectiveness.
What could go wrong: This is a small observational study, not a large trial. It cannot prove which approach is better overall, and results may not apply to all patients with kidney injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY RENAL FAILURE

Contacts and locations

Locations

Klinikum der Ludwig-Maximilians-Universität München (LMU Klinikum)

Munich, Bavaria, 81377, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.